Risdiplam (Evrysdi, Roche) is indicated for 'the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies'.
Before the December 2023 licence extension, risdiplam was indicated only for people 2 months and over.
The dosage schedule is available in the summary of product characteristics for risdiplam.
The list price is £7,900 per 60‑mg (80‑ml) vial. The company has a commercial arrangement. This makes risdiplam available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.